{"name":"Livzon Pharmaceutical Group Inc.","slug":"livzon-pharmaceutical-group-inc","ticker":"","exchange":"","domain":"livzon.com.cn","description":"","hq":"Zhuhai","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Esoprazole","genericName":"Esoprazole","slug":"esoprazole","indication":"Other","status":"marketed"},{"name":"JP-1366 simulation tablets","genericName":"JP-1366 simulation tablets","slug":"jp-1366-simulation-tablets","indication":"Other","status":"phase_3"},{"name":"LZM012","genericName":"LZM012","slug":"lzm012","indication":"Other","status":"phase_3"},{"name":"H001 Capsule 300mg-qd","genericName":"H001 Capsule 300mg-qd","slug":"h001-capsule-300mg-qd","indication":"Other","status":"phase_2"},{"name":"Ilaprazole tablet","genericName":"Ilaprazole tablet","slug":"ilaprazole-tablet","indication":"Gastric ulcer","status":"phase_3"},{"name":"amoxicillin and clarithromycin","genericName":"amoxicillin and clarithromycin","slug":"amoxicillin-and-clarithromycin","indication":"Other","status":"marketed"},{"name":"shenqifuzheng","genericName":"shenqifuzheng","slug":"shenqifuzheng","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"H001 Capsule 200mg-qd","genericName":"H001 Capsule 200mg-qd","slug":"h001-capsule-200mg-qd","indication":"Hypertension","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SARS-Cov-2 Vaccine Inactivated","genericName":"SARS-Cov-2 Vaccine Inactivated","slug":"sars-cov-2-vaccine-inactivated","indication":"Prevention of SARS-Cov-2 infection","status":"phase_3"}]}],"pipeline":[{"name":"Esoprazole","genericName":"Esoprazole","slug":"esoprazole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JP-1366 simulation tablets","genericName":"JP-1366 simulation tablets","slug":"jp-1366-simulation-tablets","phase":"phase_3","mechanism":"JP-1366 is a simulation tablet formulation designed to evaluate pharmaceutical delivery and bioavailability characteristics in clinical settings.","indications":[],"catalyst":""},{"name":"LZM012","genericName":"LZM012","slug":"lzm012","phase":"phase_3","mechanism":"LZM012 is an investigational therapeutic agent in phase 3 development by Livzon Pharmaceutical Group, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"H001 Capsule 200mg-qd","genericName":"H001 Capsule 200mg-qd","slug":"h001-capsule-200mg-qd","phase":"phase_2","mechanism":"H001 Capsule 200mg-qd is a medication that targets the renin-angiotensin system to lower blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"H001 Capsule 300mg-qd","genericName":"H001 Capsule 300mg-qd","slug":"h001-capsule-300mg-qd","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ilaprazole tablet","genericName":"Ilaprazole tablet","slug":"ilaprazole-tablet","phase":"phase_3","mechanism":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","indications":["Gastric ulcer","Duodenal ulcer","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome"],"catalyst":""},{"name":"SARS-Cov-2 Vaccine Inactivated","genericName":"SARS-Cov-2 Vaccine Inactivated","slug":"sars-cov-2-vaccine-inactivated","phase":"phase_3","mechanism":"This vaccine works by introducing inactivated SARS-Cov-2 virus to stimulate an immune response.","indications":["Prevention of SARS-Cov-2 infection"],"catalyst":""},{"name":"amoxicillin and clarithromycin","genericName":"amoxicillin and clarithromycin","slug":"amoxicillin-and-clarithromycin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"shenqifuzheng","genericName":"shenqifuzheng","slug":"shenqifuzheng","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOcWo0NHYycURBMW5xMHlma0hfRWg5TGVqN29DZmZ5Q1JaZi1oOU9HYlptLV9PZndJVER5U3duVXduSm4yVHloS25IRS1GeTc4M21iYm1YbEtyeDY5N2VibU9GMUt5bFMtTWpsNWhyLWx3SF9LNEdsRHdDZG9tVEppUXI1ZmFUeUFESlJNZ1FKVEMxcnhSa0FmdTMzdEJNb0ZseUpiRkZFY0Y5UGY0SFVj?oc=5","date":"2026-01-17","type":"pipeline","source":"Theinvestor","summary":"Chinese firm Livzon eyes nearly 78% stake in Vietnam's pharma major Imexpharm - Theinvestor","headline":"Chinese firm Livzon eyes nearly 78% stake in Vietnam's pharma major Imexpharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQbkM3SEpiNnQwaVBrVWk4Z1ZzMnlLbHlWM1hiSWU3QWgwVVJRaXF4elU0Q1ZyZjJ2ZWJRU1V2TWJnYjB0Z1A3TnRnMDVsYjY1WkZ4WS11azRycFpFVlgzQ284eC1UbkF4QkR0VER6MGlmYkljNnRMVjJUUTlsYVJCa3FsNDhpWTdKZFFrN3pBQjBrc1h3MUhMTg?oc=5","date":"2025-09-02","type":"trial","source":"BioWorld News","summary":"Phase III wins in July include Apnimed, Livzon, Takeda - BioWorld News","headline":"Phase III wins in July include Apnimed, Livzon, Takeda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPOHdHZEM0aHpfeEZYdENYenVINUg5NGc3WGZBY29vZ3BycTRUbXIzcWszWEZzTV9PN2RnYVNFRmM4eC00ZERrWUpXSV9jYmZkSFRmMHdFY2hkcGxoTUZwR2lzdlVZQS1VMHc5cGRISERjazJSMzk1ZjJGU092RGdYM3NPZHF4aU9SNW9ZSC1hazhNcTJlUEJhRmsxZ3VNalNMRXFmdWdrcjJLa21IUHc?oc=5","date":"2025-05-31","type":"pipeline","source":"IDNFinancials.com","summary":"KLBF invests USD 40 million to build pharmaceutical ingredient plant - IDNFinancials.com","headline":"KLBF invests USD 40 million to build pharmaceutical ingredient plant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQNzA1MVJEX2ZTekJpUUlEdThpZjVrS29zSkNJYU5GS2VJcURSQktNNG0zNVV4QVEyT0xOTVFrUUE4ZzJ4ZmNtamNwb2VucmtQLXVYVjdJdGIyckpLNl9UMzgtaTNwdS1fb3owZDBwWlVHZjFMQkZRdEJZSTJTaEpOal8zQkYtb0R3NDVHcHRLaFA1eDJKWm01SGlCZzAtZTd0Ync?oc=5","date":"2025-05-27","type":"deal","source":"Vietnam Investment Review - VIR","summary":"China's Livzon to acquire 65 per cent of pharmaceutical firm Imexpharm - Vietnam Investment Review - VIR","headline":"China's Livzon to acquire 65 per cent of pharmaceutical firm Imexpharm - Vietnam Investment Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMS1DNUdYN21xcTlqRzNVZHdsaWRSbWJEeU54bk4zWHptU0tuazVJUGhYcG5uOUtNSmFmU1hKcU9XMUVKdzVuM281bnAyWFk2MnQzalBqeHFiTi1ta0Q3YkpRbHc0UGpjcnlRMkdSVExmak5vZUpCRFN6SzZhS09aNHNfb2toUzdwNXlJNnRkam9IZ3hJemdwQlE3Q1JjNGpCeThVcFBTTjFkc0h0VzVOUXdZOTdpRFRp?oc=5","date":"2025-05-26","type":"deal","source":"Theinvestor","summary":"Chinese firm Livzon spends over $219 mln to acquire 64.8% stake in Vietnam's Imexpharm - Theinvestor","headline":"Chinese firm Livzon spends over $219 mln to acquire 64.8% stake in Vietnam's Imexpharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNNUVIOVRrN2RNVVE4dnl2WTdRT2hTQ3BiaHN0Nkp3R0VJU09LdHVqUFlMTjdxMW1LbkpVNjBJcDh1RjZUck1qQzJqUzU4dXhfbERGMFZBY09UeUNESUtFV28zOEtFaWxTOWhfVlFGaVd2Y2ZfbkhQNkt2Zjk2R0pEWl9HWjdQUUJvbTR6aHNsTHFGWjNUNkVKbnlla0lsWDVGM3U0c0ZleU4yVlhSZEw0bQ?oc=5","date":"2025-05-23","type":"pipeline","source":"Yicai Global","summary":"China’s Livzon Pharma to Gain Control of Vietnamese Peer IMP for USD221 Million - Yicai Global","headline":"China’s Livzon Pharma to Gain Control of Vietnamese Peer IMP for USD221 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBHeDdzd09GVlduRy1fZkVkaHJwdm1hWXJfYzRxeTNjNjZLMGpMZ05jZmc4aWh5cHQxYmF1cDZfZi1Hdkh4SUxPb1hTclJvYktCTGUtRUVFN0s2b0U0NDhsNTRrWlBEVzNORzI2N2VjZE9DdHlFMFFGVQ?oc=5","date":"2025-05-23","type":"deal","source":"DealStreetAsia","summary":"China's Livzon buys 65% in Vietnam's Imexpharm for over $219m - DealStreetAsia","headline":"China's Livzon buys 65% in Vietnam's Imexpharm for over $219m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNbTlSMjMwblNYc2dsY2ppc1pIeEdDNl9sZzJTZ3FsUUZyeWJDU1JUbmJpUFRPQ2lwZERJdlVOUlltbHBVQ2F6akFhRG8xdnF3N1doUm5YY0NMb2ZlZW83bjFpa0pnU2pRT0FLcElURV9XT0FkeC14NkJRNGVzeVRYWjh0VnRCRnVRVV9vdUpJT3BISHhpT0pkeVZTY1dqWmhqQ05mdnk4SkN5aEJFdTdieEZvcHNmSlVJNnpEU0Fn?oc=5","date":"2025-05-23","type":"deal","source":"news.tuoitre.vn","summary":"Chinese pharma giant moves to acquire majority stake in Vietnam’s Imexpharm - news.tuoitre.vn","headline":"Chinese pharma giant moves to acquire majority stake in Vietnam’s Imexpharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOQWxaa2ZEZHVHWEoyTzhtaW5tTGZ2SHBmak9iZnFpUHA1dFFQcGg4OUlweDZfLU03U2pfc2tvUTRNWXNZYWQ2czlWbnRWc0dwVzlncWxOZHRUWUI4ZDlVMW9sMGhsMm01QnZWd2JaRGNpVGNkNVIxY0NHcUZSQXVpSFZzcnpSaEE?oc=5","date":"2024-07-02","type":"pipeline","source":"thebambooworks.com","summary":"FAST NEWS: Livzon Pharma cancels repurchased H shares - thebambooworks.com","headline":"FAST NEWS: Livzon Pharma cancels repurchased H shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNTmdpSGpwQ25mdHdnNkNuVXNrLWZYY29SSmdLOHlGUmhHV295b0kzOVNZQWVDZGFWU0g3eGo1eTlYeENTOFNGc1JoS3RJaGNHYWVZSVJDQjNuYURqM3AwV19ZcE9RYXNXMGdKUUtrd3NvalhxR0x2aFJLMVh5ZmFVVUlpNThpOU5PdS1naW9XbVd0cGFaU3hZNjlTZ0wyeUdTRkdxWUVpNjNaRjhlOFRXNA?oc=5","date":"2023-08-06","type":"pipeline","source":"Bloomberg.com","summary":"China Health-Care Shares Plunge as Anti-Graft Campaign Widens - Bloomberg.com","headline":"China Health-Care Shares Plunge as Anti-Graft Campaign Widens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9sRExNVURUeXdRVVQ4VmhoZi1vRlRWRU1QNGdCd1hKOG9nZU4yU3o5U21wM3ZWcVBTRVhoMjNxbVV1TmxMY1c4czJCV2JnU1B0WjdTdU0tUFNNeVBDNE1rR3BNNjJOMU14QVZUSkh30gFyQVVfeXFMTjE1SkFxcTNDdkxxOWJrRC1OREdja0pNNW5aOHV4bFpzdGJfa1BLYTlZbW9DekFOaEcyNTh3WXItWUNSY3o3VnNzbUt6VHl5WW5BcjRNUWpMNEJjNDd1WGdqTGxDdGl3aU1XdjZYMWdpdHB3?oc=5","date":"2023-03-10","type":"deal","source":"koreabiomed.com","summary":"Onconic Therapeutics licenses out GERD drug candidate to China for $127.5 million - koreabiomed.com","headline":"Onconic Therapeutics licenses out GERD drug candidate to China for $127.5 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNcjluNlc1ZnR5N0ZtaE84QmtKazFwVU9JSmdLZmJUS2NCN0pZRDV3RmZLTlFEcXRlV2J0S3pSSnZ4eWMzZzNnU1dQY1NFOWFvZzk5c0EzS3JPYnp2c0ZCSE1SYXhsTHBUb1NKRkNXX1lXWHVHS2JLdXJsd2p2Tm16WXo4WEVHZ1piTUh6RUtRWk9ZQnJzM2I1bWNkTXp1aFA1ZzhxS3ZYY2hLZ2h0SWU5YjQxdnVvTU8taE9Vamg2QzhJa2NMSlJjTmpmMlluYnVlREVF?oc=5","date":"2022-09-02","type":"regulatory","source":"Reuters","summary":"Livzon Pharma's COVID vaccine gets approval as booster in China - Reuters","headline":"Livzon Pharma's COVID vaccine gets approval as booster in China","sentiment":"positive"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":2,"phase_3":4,"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}